Intellectual Property News & Topics - Secerna LLP

VENCLEXTA®

A to Z: Drugs in Highlight: V is for VENCLEXTA®

News A to Z Feature 30/04/2025

Our A to Z series highlights VENCLEXTA® (venetoclax) from AbbVie, a medication used to treat both chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). This article explores its mechanism of action, clinical applications, and the patent protection surrounding this important drug.

Read more

EPO

European, Industry news, News 15/05/2024

Claim interpretation using the description: Potential referral to the EPO Enlarged Board of Appeal

Copy Of 9CF4E240 F92E 4BA4 A8BE 6358DCBCA18B 1 105 C

Events, News 03/05/2024

Seas the Day takes on the Pacific in 8,000-Mile row with Secerna's support

Secerna Website Images 2023 (44)

News 28/04/2024

Unlocking Your Design's Potential: Protect Your Creation with Design Rights

Secerna Website Images 2023 (43)

News 26/04/2024

World Intellectual Property Day: Unleashing Sustainable Innovation Through IP

IP Protection For Metaverse And Other Immersive Technologies

News 18/04/2024

Secure Your Metaverse Advantage: A Guide to IP Protection

Ireland UPC

European, Industry news, News, UPC 15/04/2024

Irish Participation in the Unified Patent Court: Update on Referendum

Patent Box Article (2)

European, News 08/04/2024

The Patent Box: A Guide to Boosting Your Innovation

B012621

Events, News 04/04/2024

Secerna to attend Diagnostics North East Conference 2024

Antibodies

European, News 14/03/2024

Update on the patentability of antibodies at the European Patent Office

7 8 9 10 11 12 13 14 15 16 17